-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Nektar Therapeutics quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2010 to 2023.
- Nektar Therapeutics Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $5.39M, a 33.8% decline year-over-year.
- Nektar Therapeutics Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $24.1M, a 38.1% decline year-over-year.
- Nektar Therapeutics annual Share-based Payment Arrangement, Expense for 2023 was $33.4M, a 41.8% decline from 2022.
- Nektar Therapeutics annual Share-based Payment Arrangement, Expense for 2022 was $57.3M, a 39.5% decline from 2021.
- Nektar Therapeutics annual Share-based Payment Arrangement, Expense for 2021 was $94.7M, a 0.44% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)